Relay Therapeutics and Elevar Therapeutics Collaborate to Develop Lirafugratinib (RLY-4008) for Cholangiocarcinoma and Other Solid Tumors
Shots:
- Relay & Elevar have signed an exclusive global licensing agreement for lirafugratinib to treat FGFR2-driven cholangiocarcinoma (CCA) and other solid tumors
- Elevar gains global rights to develop & commercialize lirafugratinib, along with the responsibility of NDA submission, in exchange for up to $75M upfront & regulatory milestones, up to $425M in commercial milestones & tiered royalties of up to the low-teens percent
- Lirafugratinib is being studied in the global pivotal ReFocus trial consisting of a cohort for FGFR2-fusion CCA & cohort for other solid tumors (gastric, pancreatic, head & neck). The FDA recommended filing an NDA for FGFR2-driven CCA first, followed by a sNDA for other FGFR2-altered solid tumors
Ref: Relay Therapeutics | Image: Relay Therapeutics and Elevar Therapeutics
Related News:- Lisata Therapeutics Collaborates with Kuva Labs to Advance Non-Invasive, High-Precision Cancer Diagnostics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
